DOI:
10.1055/s-00000004
Aktuelle Neurologie
LinksClose Window
References
Chen CI, Kouroukis CT, White D et al.
Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
J Clin Oncol 2007;
25: 1570-1575
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.